Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Zelenoleucel in Phase 2 Study of Patients With AML
The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.
Magrolimab plus azacitidine in treatment-naïve AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses a Phase Ib trial (NCT03248479) of magrolimab, a novel anti-CD47 antibody, plus azacitidine in untreated acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.
Immunotherapy Inches Forward in Development of Myeloid Malignancies
Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.
Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, presents the safety and clinical activity data from a Phase I study (NCT02890329) of decitabine (DAC) plus ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the post bone marrow transplant (BMT) or treatment naïve setting.
Iodine apamistamab conditioning led to 100% bone marrow transplant rate and engr...
Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.
SIERRA: Iomab-B for pre-HSCT AML
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the prospective Phase III SIERRA trial (NCT02665065) of targeted radiotherapy with iomab-B, an anti-CD45 monoclonal antibody, in relapsed/refractory acute myeloid leukemia (AML).
Current immune checkpoint inhibitor trials in AML/MDS
Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, discusses several current trials of immune checkpoint inhibition in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) that were presented at ASH 2020.
ASH 2020 | Phase I trial of decitabine plus ipilimumab in R/R MDS & AML
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase I trial (NCT02890329) of decitabine (DAC) in combination with ipilimumab (IPI) in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), with or without prior allogeneic hematopoietic cell transplantation (allo-HCT).
iwCAR-T meeting 2020: featured sessions
During iwCAR-T 2020, some of the world’s leading clinical researchers shared their perspectives on how to place our evolving understanding in a clinical context and thereby optimize clinical care.